Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Anida Pharma Inc. has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This action is assigned to a distinct examiner, Noble E Jarrell. Consequently, Noble E Jarrell is the busiest examiner for this portfolio, managing 1 pending office action. This single matter represents the entire pending workload for the applicant at this time, creating a focused prosecution environment within the Biotechnology & Pharmaceuticals sector.
The prosecution is focused within 1 distinct art unit, which aligns with the technical classification of the filing. With only a distinct examiner and the pending office action, the applicant's experience is defined by a single point of contact within the USPTO. This allows for a targeted response strategy focused on the requirements of Noble E Jarrell and the specific standards of the 1 distinct art unit. Practitioners can dedicate their resources to this specific interaction without divergent feedback.
The presence of the pending office action suggests a streamlined interaction with the USPTO, where the outcome of the pending portfolio rests on the resolution of this matter. Consistency in communication with the examiner is essential for progress. Practitioners should prioritize the feedback from Noble E Jarrell, as his interpretation will determine the outcome for the 1 pending office action. The focused nature of this portfolio in the Biotechnology & Pharmaceuticals area allows for a dedicated strategy tailored to the examiner's preferences.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| JARRELL, NOBLE E | 1 | 80.9% | +10.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18877765 | COMPOSITIONS AND METHODS FOR TREATING HEARING AND OCULAR DISORDERS | JARRELL, NOBLE E | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18877765 | COMPOSITIONS AND METHODS FOR TREATING HEARING AND OCULAR DISORDERS | JARRELL, NOBLE E | — |
| Art Unit | Apps |
|---|---|
| 1629 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18877765 | COMPOSITIONS AND METHODS FOR TREATING HEARING AND OCULAR DISORDERS | JARRELL, NOBLE E | 1629 | §102§103 | Non-Final OA | — | Pending | Dec 20, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialAnida Pharma Inc. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Noble E Jarrell has the most, with 1 of Anida Pharma Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
